<DOC>
	<DOCNO>NCT01378585</DOCNO>
	<brief_summary>The objective study : 1 . To evaluate safety DLBS1033 comparison placebo healthy adult subject 2 . To evaluate efficacy DLBS1033 comparison placebo healthy adult subject</brief_summary>
	<brief_title>Safety Efficacy DLBS1033 Healthy Subjects</brief_title>
	<detailed_description>This study 2-arm , randomize , double-blind , placebo control , cross-over study fix dose regimen . The study involve twenty ( 20 ) healthy subject . The study comparative study safety efficacy DLBS1033 placebo . Each study period consist 14 day treatment 2-week wash-out period . The evaluation safety parameter perform Day 1 ( baseline ) , 7 , 14 ; efficacy parameter perform Day 1 , 2 , 7 , 14 .</detailed_description>
	<criteria>Male female 18 50 yearold screening Having good stable health judge basis medical history , physical examination , routine laboratory Able participate , communicate well investigator willing provide write informed consent participate study Participating clinical trial within 4 week prior screen Had major surgical procedure dental procedure within 4 week prior screen History follow medical condition : haemophilia , past medical history haemorrhagic stroke , acid peptic disease , easy bruise frequent external bleeding Any known current medical condition , judge investigator could jeopardize subject 's health interfere study evaluation Being regular medication ( ) , include traditional medicine ( ) Pregnant lactate woman ( urinary pregnancy test apply woman subject screen treatment period )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>DLBS1033</keyword>
	<keyword>safety</keyword>
	<keyword>fibrinolytic</keyword>
	<keyword>fibrinogenolytic</keyword>
	<keyword>antiplatelet</keyword>
</DOC>